<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.104103</article-id><article-id pub-id-type="publisher-id">ACM-35364</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200400000_75712611.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  细胞外基质与乳腺癌耐药
  Extracellular Matrix and Breast Cancer Resistance
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>国徽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卿</surname><given-names>晨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>昆明医科大学药学院暨云南省天然药物药理重点实验室，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>04</month><year>2020</year></pub-date><volume>10</volume><issue>04</issue><fpage>658</fpage><lpage>663</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  乳腺癌是女性癌症中发病率最高，危害最严重的肿瘤之一。乳腺癌治疗方式主要有手术、化疗、放疗、分子靶向和内分泌治疗。绝大多数患者治疗后产生的耐药，复发和转移是导致乳腺癌患者死亡的主要原因。以前对肿瘤耐药机制的研究局限于肿瘤细胞本身，以此发展的治疗方法所取得的成效并不理想。随着研究的不断深入，人们逐渐认识到细胞外基质在肿瘤耐药性的产生中也扮演着关键的角色。随着人们对细胞外基质(Extracellular Matrix, ECM)和其受体整合素(integrin, Int)的研究发现，ECM组成在癌症发展过程中持续变化，可能与化疗耐药有关。本文就细胞外基质与乳腺癌的耐药关系进行综述。
   Breast cancer is one of the tumors with the highest incidence and the most serious harm among female cancers. The main treatments for breast cancer are surgery, chemotherapy, radiotherapy, targeting and endocrine therapy. The drug resistance, recurrence and metastasis of the vast majority of patients after treatment are the main causes of death in patients with breast cancer. The previous research on the mechanism of tumor drug resistance is limited to the tumor cells themselves, and the results of the treatment methods developed by this method are not satisfactory. With the deepening of research, people gradually realize that extracellular matrix also plays a key role in the generation of tumor drug resistance. With the study of extracellular matrix (ECM) and its receptor integrin (Int), it has been found that the composition of ECM changes continuously during the development of cancer, which may be related to chemotherapy resistance. This article reviews the relationship between extracellular matrix and drug resistance of breast cancer.
 
</p></abstract><kwd-group><kwd>细胞外基质，乳腺癌，耐药, Extracellular Matrix</kwd><kwd> Breast Cancer</kwd><kwd> Drug Resistance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>细胞外基质与乳腺癌耐药<sup> </sup></title><p>王国徽，卿晨<sup>*</sup></p><p>昆明医科大学药学院暨云南省天然药物药理重点实验室，云南 昆明</p><disp-formula id="hanspub.35364-formula70"><graphic xlink:href="//html.hanspub.org/file/30-1571266x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年4月5日；录用日期：2020年4月22日；发布日期：2020年4月29日</p><disp-formula id="hanspub.35364-formula71"><graphic xlink:href="//html.hanspub.org/file/30-1571266x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>乳腺癌是女性癌症中发病率最高，危害最严重的肿瘤之一。乳腺癌治疗方式主要有手术、化疗、放疗、分子靶向和内分泌治疗。绝大多数患者治疗后产生的耐药，复发和转移是导致乳腺癌患者死亡的主要原因。以前对肿瘤耐药机制的研究局限于肿瘤细胞本身，以此发展的治疗方法所取得的成效并不理想。随着研究的不断深入，人们逐渐认识到细胞外基质在肿瘤耐药性的产生中也扮演着关键的角色。随着人们对细胞外基质(Extracellular Matrix, ECM)和其受体整合素(integrin, Int)的研究发现，ECM组成在癌症发展过程中持续变化，可能与化疗耐药有关。本文就细胞外基质与乳腺癌的耐药关系进行综述。</p><p>关键词 :细胞外基质，乳腺癌，耐药</p><disp-formula id="hanspub.35364-formula72"><graphic xlink:href="//html.hanspub.org/file/30-1571266x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/30-1571266x8_hanspub.png" /> <img src="//html.hanspub.org/file/30-1571266x9_hanspub.png" /></p></sec><sec id="s3"><title>1. ECM概述(Extracellular Matrix)</title><p>基质主要由细胞外基质(Extracellular Matrix, ECM)组成，覆盖组织基底膜和癌实质之间的区域，从而形成围绕恶性细胞的结构。ECM (细胞外基质)是细胞分泌的，由一些大分子物质构成的复杂动态网状结构，它能够维持细胞结构完整性，并以旁分泌方式参与细胞信号通路转导，对细胞生长、黏附、耐药和转移产生影响 [<xref ref-type="bibr" rid="hanspub.35364-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.35364-ref2">2</xref>]。ECM基本骨架是蛋白质，主要分为胶原蛋白、糖蛋白、聚糖蛋白、糖胺聚糖和蛋白聚糖，基质细胞蛋白和ECM重塑酶等，它们负责基质和基底膜的结构成分的产生，以及细胞因子，生长因子，ECM成分和ECM降解酶的分泌，这些分泌物可导致肿瘤微环境的局部组织重塑和结构改变。此外，研究证明基质在肿瘤发生中的决定性作用，一方面正常基质能抑制癌症的生长，另一方面活化基质促进肿瘤的发展 [<xref ref-type="bibr" rid="hanspub.35364-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.35364-ref4">4</xref>]。ECM组成在乳腺癌中与正常乳腺组织相比发生明显变化。ECM的组成不同，乳腺癌患者的临床表现存在差异。ECM的组成在癌症发展过程中持续变化，可能与治疗抵抗有关。通过靶向抑制促癌基因或促进基质介导的肿瘤信号来调节关键ECM组分的功能，可能是解决乳腺癌发展和耐药转移的一种创新的策略。因肿瘤胞外基质比较复杂，我们主要浅谈胶原蛋白、纤连蛋白、层粘连蛋白与乳腺癌耐药的关系。</p><sec id="s3_1"><title>1.1. 胶原蛋白(Collagen)</title><p>胶原蛋白(Collagen)是ECM的主要成分，以原纤维和非原纤维形式存在。胶原蛋白是细胞外基质和许多类型的软组织中最丰富的成分 [<xref ref-type="bibr" rid="hanspub.35364-ref5">5</xref>]。哺乳动物中最常见的胶原蛋白是纤维状I型胶原蛋白，是间质基质的主要成分。IV型胶原是非原纤维，是基底膜的基本组成部分。乳腺癌细胞中的胶原蛋白成分存在显著变化，其中纤维I型、III型和V型胶原蛋白增加，IV型胶原蛋白减少 [<xref ref-type="bibr" rid="hanspub.35364-ref6">6</xref>]。乳腺癌中纤维状胶原(例如I型和III型胶原)表达的增加可能与肿瘤的侵袭有关。胶原蛋白变化与乳腺癌发展之间可能有重要的关联，并且起着不同的功能作用。此外，胶原蛋白分型有很多，其中XIII型和VI型，它们与细胞之间粘附有关 [<xref ref-type="bibr" rid="hanspub.35364-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.35364-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.35364-ref9">9</xref>]，有实验发现XIII型胶原蛋白和VI型胶原蛋白在人类乳腺癌组织中的表达较高，可诱导乳腺癌抵抗失巢凋亡和对化疗药物产生耐药 [<xref ref-type="bibr" rid="hanspub.35364-ref10">10</xref>]。研究表明胶原/整合素/Src信号转导增强了对HER2和PI3K联合抑制剂的耐药，这可以被整合素β1或Src抑制剂所克服 [<xref ref-type="bibr" rid="hanspub.35364-ref11">11</xref>]。</p><p>胶原蛋白可以作为支架，促进侵袭性癌细胞或基质细胞的迁移。增强的胶原沉积能够将细胞转化为恶性表型，从而导致癌症的发展转移。另外，在乳腺癌患者中，胶原蛋白的高表达和沉积与肿瘤的发展有关，胶原蛋白的沉积增加原纤维组织改变和相关组织的生物力学特性发生重大变化。基质硬度对乳腺细胞和乳腺癌细胞的生化信号传导和细胞行为具有重要影响，细胞在高密度胶原条件下生长时，会形成无序的，高度增殖的细胞簇，其组织张力的增加，增强了细胞骨架和整联蛋白之间的联系。在乳腺上皮细胞中，基质硬度促进了丝裂原活化蛋白激酶(MAPK)途径的激活并诱导了细胞增殖。基质硬度的增强也可导致肿瘤干细胞的增加，这表明基质硬度可能通过促进肿瘤干细胞的自我更新能力来促进乳腺癌和耐药的发展。</p></sec><sec id="s3_2"><title>1.2. 纤连蛋白(Fibronectin)</title><p>纤连蛋白(Fibronectin, FN)是一种形成纤维的糖蛋白，与胶原蛋白一样，在正常乳腺组织中几乎检测不到，而在乳腺癌组织中却高度表达，并与乳腺癌的恶性程度、患者生存率有密切关系。一些研究表明FN是胶原蛋白掺入ECM所必需的，主要功能是介导细胞粘附，与其整合素受体共同参与造血干细胞的增殖、分化及细胞黏附介导耐药 [<xref ref-type="bibr" rid="hanspub.35364-ref12">12</xref>]。肿瘤细胞中FN的上调可以通过不同的机制发生，如机械压迫可以增加入侵的癌细胞表达FN，最终增加肿瘤迁移。在乳腺癌患者的循环肿瘤细胞(CTC)中已检测到FN表达。FN是已知的间充质标记，并已显示可促进转化生长因子β (TGF-β)诱导上皮间质转化。FN以不同的方式调节肿瘤细胞信号传导，并且作为乳腺癌进展的重要促进剂。例如，FN被证明在乳腺癌细胞中诱导STAT3信号通路和MAPK通路，从而促进模型系统的侵袭和转移。此外，在肿瘤细胞中，FN与类胰岛素样生长因子结合蛋白3 (IGFBP-3)和表皮生长因子(EGF)结合促进肿瘤生长；而FN不参与作用的情况下，这些生长因子抑制肿瘤生长 [<xref ref-type="bibr" rid="hanspub.35364-ref13">13</xref>]。纤连蛋白在基质中的突出作用在于纤连蛋白的能力，由于其多结构域，它能够同时与细胞表面受体(例如整联蛋白)以及胶原蛋白，蛋白聚糖和其他粘着分子结合，这种特性可介导多种细胞外基质蛋白的结合。纤连蛋白因此也被称为“主要组织者”。研究表明FN还可增加乳腺癌细胞中雌激素的活性，促进细胞生长和存活。但过多的雌激素受体活性会导致细胞迅速增殖，导致肿瘤生长，抑制纤连蛋白可以逆转乳腺癌对雌激素耐药 [<xref ref-type="bibr" rid="hanspub.35364-ref14">14</xref>]。<sup> </sup></p></sec><sec id="s3_3"><title>1.3. 层粘连蛋白(Laminin)</title><p>层粘连蛋白(Laminin, LN)形成一组大的异源三聚体糖蛋白，代表基底膜的主要非胶原蛋白。已知有12种不同的层粘连蛋白形式具有细胞和组织特异性表达，并被整联蛋白和其他受体清楚地识别。不同的同工型层粘连蛋白在乳腺癌的发展中起重要作用，其生物功能是细胞黏着于基质的介质，并与多种基底膜成分结合，调节细胞生长和分化 [<xref ref-type="bibr" rid="hanspub.35364-ref12">12</xref>]。层粘连蛋白332 (LN-332)的表达与乳腺癌侵袭有关，并且已证明源自癌细胞的LN-332通过与α6β4整联蛋白受体的相互作用促进锚定非依赖性存活。此外，已显示LN-332可通过α3整联蛋白诱导乳腺癌细胞的迁移和侵袭 [<xref ref-type="bibr" rid="hanspub.35364-ref15">15</xref>]。乳腺癌细胞与来自乳腺的原代成纤维细胞的共培养，诱导了LM-332和整联蛋白β4的表达，从而增强了对细胞凋亡的抵抗力。层粘连蛋白能调节细胞功能，如粘附，分化，迁移，表型稳定性和对凋亡的抵抗力 [<xref ref-type="bibr" rid="hanspub.35364-ref5">5</xref>]。研究显示LN在乳腺癌组织中的表达水平与肿瘤TNM分期显著相关 [<xref ref-type="bibr" rid="hanspub.35364-ref16">16</xref>]。</p></sec><sec id="s3_4"><title>1.4. 细胞外基质受体–整合素</title><p>大多数细胞需要粘附于基质生长，其粘附依赖于细胞表面整合素受体与基质的特异性结合。细胞外基质的主要受体是整合素(Integrin)，存在于细胞表面，介导着细胞与细胞外基质细胞间的粘附。整合素介导的感知，增强和重塑肿瘤基质的形成是癌症进展中的关键步骤，可支持侵袭，获得癌症干细胞特征和耐药性 [<xref ref-type="bibr" rid="hanspub.35364-ref17">17</xref>]。整联蛋白是异二聚体细胞表面受体家族，它们通过在细胞内部和外部之间形成物理连接来感知变化并触发一系列细胞反应，从而允许信号的双向“整合”来控制细胞的粘附，迁移，增殖，生存和分化,既提供细胞与细胞外基质的机械结合，又提供与癌症恶性肿瘤有关的细胞信号的产生 [<xref ref-type="bibr" rid="hanspub.35364-ref18">18</xref>]。整合素和整合素介导的粘附早已被认为是连接细胞与细胞外基质(ECM)的主要分子纽带，也是细胞与环境之间传递信号的双向枢纽 [<xref ref-type="bibr" rid="hanspub.35364-ref19">19</xref>]。整联蛋白(整合素)由两个非共价结合的跨膜亚基，即α和β亚基所组成，介导细胞和细胞之间以及细胞和细胞外基质之间的相互识别和粘附，具有联系细胞外部作用与细胞内部结构的作用。有研究表明，阻断G蛋白偶联雌激素受体(GPER)/表皮生长因子受体(EGFR)/细胞外调节蛋白激酶(ERK)/整合素β-1信号通路，可能成为增加他莫昔芬耐药乳腺癌患者敏感性的潜在靶点 [<xref ref-type="bibr" rid="hanspub.35364-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.35364-ref21">21</xref>] 整合素促进bcl-2蛋白的表达，并抑制促凋亡蛋白BIM的表达。此外，有证据表明，空缺的αvβ3整合素可通过募集caspase-8激活细胞凋亡 [<xref ref-type="bibr" rid="hanspub.35364-ref22">22</xref>]。细胞周期蛋白依赖性激酶(CDK)抑制剂p16 (也称为INK4a)的表达增强了α5β1整联蛋白的表达，恢复了多种癌细胞对失巢凋亡(Anokis)的敏感性 [<xref ref-type="bibr" rid="hanspub.35364-ref23">23</xref>]。相比之下，Laminin-5与α6β4保护癌细胞免受多种死亡信号的伤害，包括化学治疗药物诱导的死亡信号 [<xref ref-type="bibr" rid="hanspub.35364-ref24">24</xref>]。因此，取决于是否与ECM配体结合，相同的整联蛋白可能会促进或抑制癌细胞的存活。整联蛋白的连接可以促进对已锚定性癌细胞的存活，增加外源性凋亡的抵抗 [<xref ref-type="bibr" rid="hanspub.35364-ref25">25</xref>]。整联蛋白在细胞存活，增殖，运动，分化以及确保适当的细胞定位中起重要作用 [<xref ref-type="bibr" rid="hanspub.35364-ref26">26</xref>]。整合素a6还通过调节黏着斑激酶(FAK)介导的Polycomb复合蛋白B细胞特异性莫洛尼鼠白血病病毒整合位点1 (BMI-1)的诱导来促进乳腺癌的发生 [<xref ref-type="bibr" rid="hanspub.35364-ref27">27</xref>]。整联蛋白β1被认为是导致乳腺癌对拉帕替尼和曲妥珠单抗的耐药的驱动因素 [<xref ref-type="bibr" rid="hanspub.35364-ref28">28</xref>]。整联蛋白参与耐药性也可能取决于免疫应答的调节。多种药物会诱导DNA损伤反应，从而在获得耐药性时增强肿瘤细胞上整联蛋白avb3的表达，而这些具有治疗抗性的肿瘤细胞更容易被树突状细胞吞噬以抑制免疫反应 [<xref ref-type="bibr" rid="hanspub.35364-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.35364-ref30">30</xref>]。avb3配体L1细胞粘附分子(L1-CAM)在乳腺癌细胞中表达，是乳腺癌向肺转移的必要条件，它可使肿瘤细胞结合并通过肺内皮细胞扩散 [<xref ref-type="bibr" rid="hanspub.35364-ref26">26</xref>]。</p></sec></sec><sec id="s4"><title>2. 展望</title><p>肿瘤微环境与肿瘤耐药之间存在重要的关联。细胞外基质作为肿瘤微环境的重要组成部分，在肿瘤发生、发展、转移及其对药物的反应等方面均发挥重要调控功能。许多文献显示，乳腺癌干细胞可能是导致肿瘤化疗失败和复发的根本原因，乳腺癌化疗耐药–上皮间质转化–肿瘤干细胞之间有可能形成恶性循环，不断促进癌症的恶性进展。然而，乳腺癌放化疗，细胞因子和外泌体诱导EMT表型以增强肿瘤干细胞特性和侵袭转移能力的信号机制仍远未阐明。但绝大数的肿瘤细胞通过自分泌和(或)旁分泌创建的微环境在肿瘤治疗耐受和转移中具有举足轻重的作用。因此，了解肿瘤微环境与肿瘤相互作用机制是当前乳腺癌研究的重要战略，对于进一步阐述乳腺癌发生发展和耐药机制，寻找新的治疗靶标和开发更加有效的乳腺癌靶向治疗新药具有重要的理论和临床意义。</p></sec><sec id="s5"><title>文章引用</title><p>王国徽,卿 晨. 细胞外基质与乳腺癌耐药Extracellular Matrix and Breast Cancer Resistance[J]. 临床医学进展, 2020, 10(04): 658-663. https://doi.org/10.12677/ACM.2020.104103</p></sec><sec id="s6"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35364-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Jena, M.K. and Janjanam, J. (2018) Role of Extracellular Matrix in Breast Cancer Development: A Brief Update. F1000Research, 7, 274. &lt;br&gt;https://doi.org/10.12688/f1000research.14133.2</mixed-citation></ref><ref id="hanspub.35364-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Oudin, M.J.W.V. (2016) Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis. Cold Spring Harbor Symposia on Quantitative Biology, 81, 189-205. 
&lt;br&gt;https://doi.org/10.1101/sqb.2016.81.030817</mixed-citation></ref><ref id="hanspub.35364-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Barcelloshoff, M.H. (2000) The Influence of the Microenvi-ronment on the Malignant Phenotype. Molecular Medicine Today, 6, 324-329. &lt;br&gt;https://doi.org/10.1016/S1357-4310(00)01756-1</mixed-citation></ref><ref id="hanspub.35364-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Beacham, D.A. and Cukierman, E. (2005) Stromagenesis: The Changing Face of Fibroblastic Microenvironments during Tumor Progression. Seminars in Cancer Biology, 15, 329-341. &lt;br&gt;https://doi.org/10.1016/j.semcancer.2005.05.003</mixed-citation></ref><ref id="hanspub.35364-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Halper, J. and Kjaer, M. (2014) Basic Components of Connective Tissues and Extracellular Matrix: Elastin, Fibrillin, Fibulins, Fibrinogen, Fibronectin, Laminin, Tenascins and Thrombospondins. Advances in Experimental Medicine &amp; Biology, 3, 31-47. &lt;br&gt;https://doi.org/10.1007/978-94-007-7893-1_3</mixed-citation></ref><ref id="hanspub.35364-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">马婕, 邱涵, 张倩, 徐正丰. VI型胶原蛋白在乳腺癌组织中的表达及临床意义[J]. 中国妇幼健康研究, 2016, 27(1): 303-304.</mixed-citation></ref><ref id="hanspub.35364-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">王玉珍, 段惠军, 陈建国, 呼亚伟, 李英敏. 层粘蛋白和Ⅳ型胶原在乳腺癌的表达[J]. 河北医科大学学报. 2001(2): 10-2+70.</mixed-citation></ref><ref id="hanspub.35364-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Insua-Rodríguez, J. and Oskarsson, T. (2015) The Extracellular Matrix in Breast Cancer. Advanced Drug Delivery Reviews, 97, 41-55. &lt;br&gt;https://doi.org/10.1016/j.addr.2015.12.017</mixed-citation></ref><ref id="hanspub.35364-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hansen, U. (2013) The Expanded Collagen VI Family: New Chains and New Questions. Connective Tissue Research, 54, 345-350.</mixed-citation></ref><ref id="hanspub.35364-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Faller, W.J., Rafferty, M., Hegarty, S., Gremel, G., Ryan, D., Fraga, M.F., et al. (2010) Metallothionein 1E Is Methylated in Malignant Melanoma and Increases Sensitivity to Cisplatin-Induced Apoptosis. Melanoma Research, 20, 392-400.  
&lt;br&gt;https://doi.org/10.1097/CMR.0b013e32833d32a6</mixed-citation></ref><ref id="hanspub.35364-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hanker, A.B., Estrada, M.V., Bianchini, G., Moore, P.D., Zhao, J., Cheng, F., et al. (2017) Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Research, 77, 3280-3292. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-16-2808</mixed-citation></ref><ref id="hanspub.35364-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Valkenburg, K.C., de Groot, A.E. and Pienta, K.J. (2018) Targeting the Tumour Stroma to Improve Cancer Therapy. Nature Reviews Clinical Oncology, 15, 366-381. &lt;br&gt;https://doi.org/10.1038/s41571-018-0007-1</mixed-citation></ref><ref id="hanspub.35364-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Morais, C., Small, D.M., Vesey, D.A., Martin, J., Johnson, D.W. and Gobe, G.C. (2014) Fibronectin and Transforming Growth Factor Beta Contribute to Erythropoietin Resistance and Maladaptive Cardiac Hypertrophy. Biochemical and Biophysical Research Communications, 444, 332-337. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2014.01.047</mixed-citation></ref><ref id="hanspub.35364-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wang, K., Wu, F., Seo, B.R., Fischbach, C., Chen, W., Hsu, L., et al. (2017) Breast Cancer Cells Alter the Dynamics of Stromal Fibronectin-Collagen Interactions. Matrix Biology, 60-61, 86-95.  
&lt;br&gt;https://doi.org/10.1016/j.matbio.2016.08.001</mixed-citation></ref><ref id="hanspub.35364-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Amalia, A., Serena, M., Letizia, P., et al. (2016) Hepatic Stellate Cells Induce Hepatocellular Carcinoma Cell Resistance to Sorafenib through the Laminin-332/α3 Integrin Axis Recovery of Focal Adhesion Kinase Ubiquitination.</mixed-citation></ref><ref id="hanspub.35364-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Qiu, X., Tan, H.S., Fu, D.Y., et al. (2018) Laminin Is over Expressed in Breast Cancer and Facilitate Cancer Cell Metastasis.</mixed-citation></ref><ref id="hanspub.35364-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Nithikoon, A. and Pithi, C. (2019) Integrin as a Molecular Target for Anti-Cancer Approaches in Lung Cancer. Anticancer Research, 39, 541-548. &lt;br&gt;https://doi.org/10.21873/anticanres.13146</mixed-citation></ref><ref id="hanspub.35364-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Seguin, L., Desgrosellier, J.S., Weis, S.M. and Cheresh, D.A. (2015) Integrins and Cancer: Regulators of Cancer Stemness, Metastasis, and Drug Resistance. Trends in Cell Biology, 25, 234-240.  
&lt;br&gt;https://doi.org/10.1016/j.tcb.2014.12.006</mixed-citation></ref><ref id="hanspub.35364-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kechagia, J.Z., Ivaska, J. and Roca-Cusachs, P. (2019) Integrins as Biomechanical Sensors of the Microenvironment. Nature Reviews Molecular Cell Biology, 20, 457-473. &lt;br&gt;https://doi.org/10.1038/s41580-019-0134-2</mixed-citation></ref><ref id="hanspub.35364-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">温敏, 刘莹莹, 徐金锋, 孙瑜, 董发进, 苏莉莉, 郭凤娟. 乳腺癌肿瘤微环境相关治疗靶点的研究进展[J]. 广东医学, 2019, 40(7): 908-912.</mixed-citation></ref><ref id="hanspub.35364-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, J., Yang, L., Tu, G., Zhu, Q., Chen, M.S., Cheng, H., Luo, H.J., Fu, W.J., Li, Z.H. and Yang, G.L. (2015) Acquisition of Epithelial-Mesenchymal Transition Phenotype in the Tamoxifen-Resistant Breast Cancer Cell: A New Role for G Protein-Coupled Estrogen Receptor in Mediating Tamoxifen Resistance through Cancer-Associated Fibroblast-Derived Fibronectin and β1-Integrin Signaling Pathway in Tumor Cells. Breast Cancer Research, 17, 1-18. 
&lt;br&gt;https://doi.org/10.1186/s13058-015-0579-y</mixed-citation></ref><ref id="hanspub.35364-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ren, X., Xu, J., Cooper, J.P., Kang, H. and Erdreich-Epstein, A. (2012) c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins αvβ3 and αvβ5. PLoS ONE, 7, e42291. 
&lt;br&gt;https://doi.org/10.1371/journal.pone.0042291</mixed-citation></ref><ref id="hanspub.35364-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chen, H.-Y., Pan, L., Yang, H.-L., Xia, P., Yu, W.-C., Tang, W.-Q., et al. (2018) Integrin α5β1 Suppresses rBMSCs Anoikis and Promotes Nitric Oxide Production. Biomedecine &amp; Pharmacotherapie, 99, 1-8. 
&lt;br&gt;https://doi.org/10.1016/j.biopha.2018.01.038</mixed-citation></ref><ref id="hanspub.35364-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Miyata, K. and Takebe, J. (2013) Anodized-Hydrothermally Treated Titanium with a Nanotopographic Surface Structure Regulates Integrin-α6β4 and Laminin-5 Gene Expression in Adherent Murine Gingival Epithelial Cells. The Journal of Prosthodontic Research, 57, 99-108. &lt;br&gt;https://doi.org/10.1016/j.jpor.2012.12.002</mixed-citation></ref><ref id="hanspub.35364-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">王莹, 姜媛媛, 李国军, 王冰. 整合素在肿瘤发展中的作用[J]. 中国化工贸易, 2017, 9(20): 235.</mixed-citation></ref><ref id="hanspub.35364-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Danen, E. (2005) Integrins: Regulators of Tissue Function and Cancer Progres-sion. Current Pharmaceutical Design, 11, 881-891. &lt;br&gt;https://doi.org/10.2174/1381612053381756</mixed-citation></ref><ref id="hanspub.35364-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Campbell, P.S. (2019) AhR Ligand Aminoflavone Suppresses α6-Integrin-Src-Akt Signaling to Attenuate Tamoxifen Resistance in Breast Cancer Cells. Journal of Cellular Physiology, 234, 108-121. &lt;br&gt;https://doi.org/10.1002/jcp.27013</mixed-citation></ref><ref id="hanspub.35364-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Naci, D., Vuori, K. and Aoudjit, F. (2015) α2β1 Integrin in Cancer Development and Chemoresistance. Seminars in Cancer Biology, 35, 145-153. &lt;br&gt;https://doi.org/10.1016/j.semcancer.2015.08.004</mixed-citation></ref><ref id="hanspub.35364-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Weaver, V.M., Lelièvre, S., Lakins, J.N., Chrenek, M.A. and Bissell, M.J. (2002) Beta4 Integrin-Dependent Formation of Polarized Three-Dimensional Architecture Confers Resistance to Apoptosis in Normal and Malignant Mammary Epithelium. Cancer Cell, 2, 205-216. &lt;br&gt;https://doi.org/10.1016/S1535-6108(02)00125-3</mixed-citation></ref><ref id="hanspub.35364-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Stupack, D.G. (2001) Apoptosis of Adherent Cells by Re-cruitment of Caspase-8 to Unligated Integrins. Journal of Cell Biology, 155, 459-470. &lt;br&gt;https://doi.org/10.1083/jcb.200106070</mixed-citation></ref></ref-list></back></article>